Echo IQ Limited (ASX:EIQ), an AI and medical technology company based in Sydney, has issued 1,000,000 fully paid ordinary shares following the exercise of unlisted options priced at $0.25, expiring 29 November 2026, according to a cleansing notice lodged with the exchange on 20 November 2026.
Key Points
- Echo IQ issued 1,000,000 fully paid ordinary shares pursuant to the exercise of unlisted options at $0.25, expiring 29 November 2026.
- The shares were issued without disclosure to investors under Part 6D.2, in reliance on Section 708A(5) of the Corporations Act 2001.
- The company confirmed compliance with Chapter 2M and Sections 674 and 674A of the Corporations Act 2001 as at the date of the notice.
- The company stated there is no excluded information as at the date of the notice for the purposes of Sections 708A(7) and (8) of the Corporations Act 2001.
Section 708A Cleansing Notice Details
Echo IQ filed the notice pursuant to Section 708A(5)(e) of the Corporations Act 2001. The filing states that the 1,000,000 fully paid ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001, with the company relying on Section 708A(5) as the basis for the issue. The shares form part of a class of securities quoted on the Australian Securities Exchange. The notice was authorised for release by the Executive Chairman of Echo IQ Limited and is dated 20 November 2026.
Regulatory Compliance Statements
As at the date of the cleansing notice, Echo IQ confirmed it had complied with the provisions of Chapter 2M of the Corporations Act 2001, which governs financial reporting obligations for companies, as well as Section 674 and Section 674A of the Corporations Act 2001, which relate to continuous disclosure obligations. The company further disclosed that there is no excluded information as at the date of the notice for the purposes of Sections 708A(7) and 708A(8) of the Corporations Act 2001.
Company Background
Echo IQ is an AI and medical technology company that uses AI-driven technology and proprietary software to improve decision making in cardiology. The company is headquartered in Sydney, Australia, and its shares are listed on the Australian Securities Exchange under the ticker EIQ. The options exercised were unlisted options with an exercise price of $0.25 and an expiry date of 29 November 2026, as disclosed in the filing.




Please wait processing your request...